Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage

3 Jan 2017

Abstract excerpt

The Orphan Drug Act of 1983 was intended to incentivize the development of pharmaceutical products for rare diseases by providing manufacturers with the opportunity to earn grants, tax credits, fee waivers, and seven years of post-approval market exclusivity for the approved indication.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Health Systems, Economic Evaluations, Quality of Life
Share to Pharmaceutical studies and practices

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 28045970
DOI: 10.1371/journal.pmed.1002190

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act CoveragePMID 28045970Read ↗

Considerations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease.Semantic proximity Read ↗

Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patientsSemantic proximity Read ↗

Quantifying hope: An EU perspective of rare disease therapeutic space and market dynamicsSemantic proximity Read ↗

Biomarker research and leading causes of death worldwide: a rather feeble relationshipSemantic proximity Read ↗

A State-of-the-Art Roadmap for Biomarker-Driven Drug Development in the Era of Personalized TherapiesSemantic proximity Read ↗

Reimbursement of pharmacogenetic tests at a tertiary academic medical center in the United StatesSemantic proximity Read ↗

Regulation of biomarker analysis: what can be translated in the clinic?Semantic proximity Read ↗

Characteristics and data reporting of rare disease clinical trials: Getting better but still room for improvementSemantic proximity Read ↗

In Pursuit of Greater Reproducibility and Credibility of Early Clinical Biomarker ResearchSemantic proximity Read ↗

PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.Semantic proximity Read ↗

The outcome of more than 3 decades of orphan drug development in alpha-1-antitypsin deficiency – a cross sectional analysis of the FDA Orphan Drug Product designation databaseSemantic proximity Read ↗

dbGaP data access requests: a call for greater transparency.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.